Status and phase
Conditions
Treatments
About
A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and multiple (Part 2) oral doses.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
126 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Ullrich Schwertschlag, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal